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Abstract
The Peutz-Jeghers syndrome (PJS) is an autosomal-dominant hamartomatous polyposis syndrome characterized
by mucocutaneous pigmentation, gastrointestinal polyps and the increased risk of multiple cancers. The causative
point mutation in the STK11 gene of most patients accounts for about 30% of the cases of partial and complete gene
deletion. This is a report on a girl with PJS features, learning difficulties, dysmorphic features and cardiac malforma-
tion, bearing a de novo 1.1 Mb deletion at 19p13.3. This deletion encompasses at least 47 genes, including STK11.
This is the first report on 19p13.3 deletion associated with a PJS phenotype, as well as other atypical manifestations,
thereby implying a new contiguous gene syndrome.
Key words: 19p13.3 deletion, comparative genomic hybridization array, contiguous gene syndrome,
Peutz-Jeghers syndrome, STK11 gene.
Received: April 15, 2011; Accepted: July 14, 2011.
The Peutz-Jeghers syndrome (PJS) is a rare auto-
somal-dominant disease characterized by gastrointestinal
polyposis and mucocutaneous pigmentation. It is associ-
ated with a predisposition for various types of benign and
malignant gastrointestinal and extra-intestinal tumors
(Giardiello and Trimbath, 2006). In 1998, point mutations
in the STK11(LKB1) gene were described as inducing PJS
(Hemminki et al., 1998; Jenne et al., 1998). STK11,
mapped at 19p13.3, encodes a serine-threonine protein
kinase that acts as a regulator of cell-cycle metabolism and
cell polarity, with evidence of tumor suppressor functions
(Forcet et al., 2005).
Germline point mutations in STK11 have been identi-
fied in most patients with PJS, with partial or whole gene
deletion in approximately 30% of these (Aretz et al., 2005;
Resta et al., 2010). Some PJS individuals with deletions of
up to 250 kb, encompassing STK11 and neighboring genes,
have been described (Le Meur et al., 2004; Resta et al.,
2010). Only one patient with a large deletion, between
220-250 kb, presented other features in addition to PJS
characteristics,namelylearningdisabilityandscoliosis(Le
Meur et al., 2004). Carriers of larger deletions at 19p13.3,
but without PJS features, have been reported (Archer et al.,
2005; Hurgoiu and Suciu, 1984). Here, a patient with PJS,
as well as other atypical clinical manifestations due to a
~1.1 Mb deletion at 19p13.3, is described.
The patient, a girl, was the second child of a non-con-
sanguineous and healthy couple. The father was 30-years-
old, and the mother 28, at the time of birth. The first child,
anapparentlynormalboyatbirth,wasstillbornafteracom-
plicated delivery. The girl was delivered at term, by caesar-
ean section, after an uncomplicated pregnancy. Birth
weight was 2500 g, body length 44 cm, and Apgar scores 3
and 5. For the first 18 days, she required intensive care-unit
intervention with supplemental oxygen. At five days of
age, atrial and ventricular septal defects were diagnosed,
which were surgically corrected at 10 months. Hypotonia
was noted in the first year of life. She had a seizure at five
years-old, without recurrence. She started walking at age
five, when she also developed diurnal sphincter control.
The onset of menarche occurred at 13, followed by normal
menstrual periods. At 14, learning disability was apparent,
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Short Communicationtogether with the absence of nocturnal sphincter control.
Herheightwas153.5cm(10
thcentile),weight48.5kg(10
th
centile) and head circumference 54 cm (50
th centile). High
myopiaof-13dioptersaffectedbotheyes.Dysmorphicfea-
tures included epicanthic folds, high nasal bridge, mild
kyphoscoliosis, cubitus valgus and a wide gap between the
1st and 2nd toes. Black pigment spots were noted on the
eyelids, nose, cheeks and lips (Figure 1).
At 14 years-old, medical evaluation included normal
karyotype, renal ultrasound, magnetic resonance-imaging
of the brain, electroencephalogram and electroneuromyo-
graphy and colonoscopy. Vertebral column radiography
documented mild kyphoscoliosis and hyperlordosis. Poly-
somnography revealed 63 apneic episodes.
Microarray-based comparative genomic hybridiza-
tion (array CGH) was initially carried out with DNA ex-
tracted from the peripheral blood of the patient and her
parents, using a bacterial artificial chromosome (BAC)
microarray (the SignatureChip Whole Genome; Signature
Genomic Laboratories, Spokane, WA), as previously de-
scribed(Ballifetal.,2008).Theextentofdeletioninthepa-
tient was more precisely defined using a 135K-feature
oligonucleotide-based microarray (SignatureChip Oligo
SolutionTM, version 2.0, designed by Signature Genomics
andmanufacturedbyRocheNimblegen,Madison,WI),ac-
cording to previously described methods (Duker et al.,
2010). Fluorescence in situ hybridization (FISH) was with
metaphase cells from the patient and her parents, using
BAC clone CTD-2589F14 from 19p13.3, according to
Traylor et al. (2009). Interphase FISH using BAC clone
CTD-2086M18 from 3q29 was also carried out on the pa-
tient, according to Ballif et al. (2008).
Oligonucleotide-based array CGH revealed an ap-
proximately 1.1 Mb deletion at 19p13.3 (chr19:213,080-
1,322,552, UCSC hg 18 in the patient). Normal FISH and
BAC-based array results in her parents pointed to this dele-
tion as being de novo. Furthermore, the patient also pre-
sented 760 kb duplication at 3q29
(chr3:197,254,006-198,014,826). As BAC-based
microarray analysis of the parents showed the mother as
carrying this same duplication, this was considered as ma-
ternal in origin.
The ~1.1 Mb deletion in our patient encompassed at
least 47 genes: PPAP2C, MIER2, THEG, C2CD4C, SHC2
ODF3L2,, MADCAM1, C19orf20, CDC34, GZMM, BSG,
HCN2, POLRMT, FGF22, FSTL3, RNF126, PRSSL1,
PALM, C19orf21, PTBP1, LPPR3, AZU1, PRTN3,
ELANE, CFD, MED16, C19orf22, KISS1R, ARID3A,
WDR18, GRIN3B, C19orf6, CNN2, ABCA7, HMHA1,
POLR2E, GPX4, SBNO2, STK11, C19orf26, ATP5D,
MIDN, C19orf23, CIRBP, C19orf24, EFNA2, and MUM1
(Figure 2).
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Figure 1 - Patient at 14 years of age. A and B - Facial appearance. Note the epicanthic folds, high nasal bridge and black pigment spots on the eyelids,
nose, cheeks and lips. C - Note the wide gap between the first and second toes.The girl, although here described as the third patient
reported with a larger than 1 Mb deletion at 19p13.3, is the
first presenting a PJS phenotype and other atypical clinical
manifestations in association with this deletion. The two-
months-old patient reported by Hurgoiu and Suciu (1984),
presented, through ocular findings, primitive vitreous body
and punched-out lesions of the retina. Besides being deaf,
spastic, microcephalic and anemic, there were epicanthic
folds and umbilical hernia. By karyotyping, his deletion
was defined as 19p13-pter, with no further molecular char-
acterization, thus thwarting a clear comparison with the de-
letion in our patient.
The male patient described by Archer et al. (2005)
presented unusual facial appearance, cleft palate, mixed
sensorineural and conductive deafness, a congenital heart
defect, keloid scaring, immune dysfunction, seizures and
moderate learning difficulties. His ~1.2 Mb deletion in-
volved approximately 60 genes. After FISH, a BAC clone
containing STK11 gene was found to be partially deleted,
thus impeding gene-status definition. Features shared with
our patient were a congenital heart defect and learning dif-
ficulties. The aforementioned congenital heart defect was
characterized by pulmonary stenosis with dysplastic
tricuspid valve, a ventricular septal defect (VSD) and mild
over-ride of the aorta. Two of his five siblings, although
withoutthe19p13.3deletion,alsoborecongenitalheartde-
fects,ascoarctationoftheaorta,bicuspidaorticvalveanda
VSD in one, and an atrioseptal defect in the other. Notwith-
standing, the authors suggested that the cardiac defect in
their patient was more likely related to deletion of the
19p13.3 chromosome, than to a family-trait.
Some of the genes mapped to the deleted segment,
bothinourpatientandthatofArcheretal.(2005),mightbe
relatedtocardiacanomalies.CNN2(calponin2)codesfora
protein that is involved in smooth-muscle contraction.
Shown to be expressed in mouse embryonic and adult
hearts (Masuda et al., 1996), it appears to be co-localized
with vinculin in the cell-to-cell junctions of
cardiomyocytes. SHC2 (SHC transforming protein 2), be-
sides encoding a member of the SHC family of cell signal-
ing proteins, interacts with the vascular endothelial growth
factor(VEGF)(Ratcliffeetal.,2002).TheVEGFsignaling
system plays a critical role in heart formation (Vannay et
al., 2006; Zhao et al, 2010). FSTL3 (follistatin like 3), a de-
velopmental gene coding for a member of the follistatin-
module protein family, is composed of extracellular ma-
trix-associated glycoproteins. It acts by binding morpho-
genesis or growth and differentiation factors, as well as
regulating their activity during development (Arai et al.,
2003). FSTL, abundantly expressed in fetal and adult
mouse hearts, neutralizes several transforming growth fac-
tor-beta (TGF-beta) superfamily members, this including
myostatin (Takehara-Kasamatsu et al., 2007). FSTL3 also
binds both activin and BMP2 (Tsuchida et al., 2000). A
hypomorphic BMP2 (bone morphogenetic protein 2) re-
ceptor has been associated with congenital heart defects in
murine models (Delot et al., 2003). Recently BMP2-
induced kinase was associated with the high level myopia
(Liu et al., 2009) present in our patient. Therefore, haplo-
insufficiencyofFSTL3maycontributetobothheartdefects
and ocular anomalies.
Another gene, possibly related to cardiac malforma-
tion, is PTBP1 (polypyrimidine tract binding protein 1).
This belongs to a subfamily of ubiquitously expressed het-
erogeneous nuclear ribonucleoproteins, RNA-binding pro-
teins that appear to influence mRNA processing. Zhang et
al. (2009) showed that PTB, besides contributing to apop-
totic gene expression, also modulates susceptibility to
caspase activation by differentiating rat cardiomyocytes.
Cardiac morphologic abnormalities were also found in
mice deficient in key regulators of caspase-dependent sig-
naling.
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Figure 2 - Deletion at 19p13.3. Array-CGH analysis showed a single-copy loss of 84 oligonucleotide probes at 19p13.3, approximately 1.1 Mb in size
(chr19:213,080-1,322,552, UCSC March 2006 hg18 assembly). Genes encompassed by the deletion are listed.(DECIPHER) lists large 19p13.3 deletion cases. Pheno-
types were not reported in a patient with an 0.72 Mb de
novo deletion and another with an 0.89 Mb, whose parents
had not been analyzed. Another patient with an atrial sep-
tum defect and intellectual disability, besides bearing an
0.58 Mb deletion at 19p13.3 which did not encompass
STK11,alsocarried2Mbduplicationat16q24.Parentshad
also not been analyzed.
Le Meur et al. (2004) reported a PJS patient with
learning disabilities, scoliosis and paternally inherited type
1neurofibromatosis(NF1).His250kbdeletionat19p13.3,
including STK11, was inherited from his mother, also diag-
nosed as PJS. The concomitant presence of NF1 makes it
difficult to attribute learning disability to 19p13.3 deletion.
This deletion also removed GRIN3B, CNN2, ABCA7,
HMHA1, POLR2E, GPX4 and SBNO2 genes.
The PJS features in our patient can be attributed to
haploinsufficiency for STK11. STK11 haploinsufficiency
could not be proved in the patient with a deletion at
19p13.3, but without PJS features, as reported by Archer et
al. (2005). Whereas, it was proposed that this patient might
have a milder and undiagnosed disease or that haploin-
sufficiency for STK11 might not cause PJS, in the very
same year, Aretz et al. (2005) reported that approximately
30% of the patients with PJS presented partial or complete
STK11 deletion, and STK11 haploinsufficiency was con-
firmed as a cause for PJS in other patients (Hearle et al.,
2006; Resta et al., 2010; Volikos et al., 2006).
Resta et al. (2010), on evaluating 51 patients with
PJS, found 15 STK11 deletions ranging from 2.9 to 180 kb,
six of which including additional genes. As these patients
presented classical PJS features, but no further anomalies,
they proposed that haploinsufficiency of the contiguous
genes SBNO2, C19orf26, ATP5D, MIDN, C19orf23,
CIRBP, C19orf24 and EFNA2 did not impact the pheno-
type. These genes, also deleted in our patient, should not be
considered as candidates for her atypical clinical features.
In addition to the 19p13.3 deletion, our patient
showed a maternally inherited 760 kb duplication at 3q29,
encompassing 10 genes. Most probably it is a copy number
variation without overt clinical impact, as this was also
present in her phenotypically normal mother.
In conclusion we describe a patient with PJS and
other clinical findings associated with a deletion at
19p13.3. This case illustrates the need of screening for
large deletions those patients who present PJS together
with atypical clinical features.
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